 |
Case Report
Iris metastasis secondary to prostate adenocarcinoma: A case report and literature review
1 Resident, MD, Department of Ophthalmology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
2 Consultant, MD, Department of Ophthalmology, AZ Delta, Sint-Rembertlaan 21, 8820 Torhout, Belgium
Address correspondence to:
Pauline Casselman
University Hospitals Leuven, Herestraat 49, 3000 Leuven,
Belgium
Message to Corresponding Author
Article ID: 100018Z17CP2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Casselman P, Van Meer N. Iris metastasis secondary to prostate adenocarcinoma: A case report and literature review. J Case Rep Images Opthalmol 2021;4:100018Z17CP2021.ABSTRACT
Introduction: Despite prostate carcinoma being relatively frequent, iris metastases are extremely uncommon. Only a few cases of iris metastases secondary to prostate adenocarcinoma have been published so far.
Case Report: A 75-year-old patient with a four-year history of metastatic prostate adenocarcinoma (cT3N0M1, Gleason 9) presented with reduced vision in his right eye for two days. Slit lamp biomicroscopy revealed a voluminous amelanotic mass in the superotemporal iris. Given his poor general condition, the patient did not want further investigations or treatment. He died two weeks after diagnosis of the iris metastasis.
Conclusion: Iris metastases secondary to prostate cancer are rare. The patient usually complains of decreased or blurred vision. Ophthalmoscopy often reveals a yellowish-white or pink, nodular, vascularized mass. Fine-needle aspiration biopsy is recommended if the primary tumor is not yet known. The standard treatment is radiotherapy, although alternative therapies, such as hormonal therapy are described in literature. Nevertheless, iris metastases are usually associated with an advanced oncological disease and hence a limited life expectancy.
Keywords: Case report, Iris metastasis, Prostate adenocarcinoma, Radiation therapy
SUPPORTING INFORMATION
Author Contributions
Pauline Casselman - Substantial contributions to conception and design, Analysis of data, Drafting the article, Final approval of the version to be published
Nathalie VanMeer - Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Pauline Casselman et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
